ReviewOncoTargets and therapy2019
Update on liquid biopsy in clinical management of non-small cell lung cancer.
Review in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy of liquid biopsy for genetic mutations determination in non-small cell lung cancer: a systematic review on literatures.BMC cancer · 2025Pooled it
- Liquid biopsy in non-small cell lung cancer: a meta-analysis of state-of-the-art and future perspectives.Frontiers in genetics · 2023Pooled it
- Lung cancer screening based on plasma-derived exosomes via droplet coating deposition Raman spectroscopy and machine learning.Biomedical optics express · 2026Article
- Innovative Applications of Nanopore Technology in Tumor Screening: An Exosome-Centric Approach.Biosensors · 2025Review
- Minimally invasive biomarkers for triaging lung nodules-challenges and future perspectives.Cancer metastasis reviews · 2025Review
- Lung Cancer Diagnosis and Prognostic Monitoring Through Cell-Free RNA via Liquid Biopsy.Therapeutics and clinical risk management · 2025Review
- Dual-Modal Aptasensor for Sensitive Detection of Non-Small Cell Lung Cancer Exosomes Utilizing Two-Dimensional Nanopaper Co@g-CACS omega · 2024Article
- MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature.Therapeutic advances in medical oncology · 2024Review
- Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer withTranslational lung cancer research · 2023Article
- Sequence-Based Platforms for Discovering Biomarkers in Liquid Biopsy of Non-Small-Cell Lung Cancer.Cancers · 2023Review
- Favorable Conditions for the Detection of EGFR T790M Mutation Using Plasma Sample in Patients with Non-Small-Cell Lung Cancer.Cancers · 2023Article
- Accelerating the Development and Validation of Liquid Biopsy for Early Cancer Screening and Treatment Tailoring.Healthcare (Basel, Switzerland) · 2022Article
- RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients WithJTO clinical and research reports · 2022Article
- Towards Machine Learning-Aided Lung Cancer Clinical Routines: Approaches and Open Challenges.Journal of personalized medicine · 2022Review
- The Role of Exosomes and Their Applications in Cancer.International journal of molecular sciences · 2021Review
- Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated MetastaticJTO clinical and research reports · 2021Article
- Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab.Oncotarget · 2021Article
- Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies.Translational lung cancer research · 2021Article
- Article
- Recent Trends of Lung Cancer in Korea.Tuberculosis and respiratory diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer, a leading cause of cancer-related mortality, has a low rate of early diagnosis and a poor prognosis for advanced stages. Recent advances in further mastery of the biology of tumors promote the diagnosis and therapy, especially for non-small cell lung cancer (NSCLC). However, tumor tissue-based information is often not available in most cases due to the invasive and high risk nature of the tumor biopsy procedures. Liquid biopsy, based on the multiple liquid samples including circulating tumor cells (CTC), circulating tumor DNA (ctDNA), and tumor-derived exosome obtained from blood or urine as well as other body fluids, can also provide valuable tumor-related information, playing an important role in management of NSCLC in clinical practice. It is widely believed that concordance of detection for tumor by liquid samples in comparison with tissue biopsy for both early and advanced stage NSCLC patients is optimistic. We herein review the current and future clinical application of liquid biopsy, including early diagnosis and management of precise personalized treatment in lung cancer. The future directions of development for liquid biopsy are also discussed in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.